BioAge Labs, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$194M
Investors
32
Min Invest
$3
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
BioAge Labs, Inc. is a Delaware corporation that filed a Form D with the SEC on February 13, 2024 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. BioAge Labs, Inc. reported $194,390,799 sold from 32 investors of a $194,390,799 total offering as of the Form D filed February 13, 2024. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $3. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 5885 Hollis Street, Suite 370, Emeryville, CA 94608.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
2
latest Feb 13, 2024
Critical / warning
0 / 0
2 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
closed
Latest event Large raise · Feb 13, 2024
SEC.govInvestor
- 2 filing events with values and deltas, latest 2024-02-13, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Kristen Fortney
Executive Officer, Director · Richmond, CA
Eric Morgen
Director · Richmond, CA
Vijay Pande
Director · Richmond, CA
Jason Coloma
Director · Richmond, CA
Rehka Hemrajani
Director · Richmond, CA
James Healy
Director · Richmond, CA
Patrick Enright
Director · Richmond, CA
Dov Goldstein
Executive Officer · Richmond, CA
Questions About BioAge Labs, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is BioAge Labs, Inc.?
BioAge Labs, Inc. is a Delaware corporation that filed a Form D with the SEC on February 13, 2024 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.
Is BioAge Labs, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. BioAge Labs, Inc. filed a Form D with the SEC on February 13, 2024 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $194,390,799 sold to 32 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is BioAge Labs, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that BioAge Labs, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has BioAge Labs, Inc. raised?
BioAge Labs, Inc. reported $194,390,799 sold from 32 investors of a $194,390,799 total offering as of the Form D filed February 13, 2024.
Who can invest in BioAge Labs, Inc.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $3.
What is the minimum investment in BioAge Labs, Inc.?
The Form D lists $3 as the minimum investment accepted from any outside investor as of February 13, 2024. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling BioAge Labs, Inc. and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.
Who is behind BioAge Labs, Inc.?
The Form D lists 8 related persons: Kristen Fortney, executive officer, director; Eric Morgen, director; Vijay Pande, director; Jason Coloma, director; Rehka Hemrajani, director; James Healy, director; Patrick Enright, director; Dov Goldstein, executive officer. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is BioAge Labs, Inc. located?
The issuer's address on its SEC filings is 5885 Hollis Street, Suite 370, Emeryville, CA 94608. Its phone number of record is 510-806-1445. It is organized under the laws of Delaware.
How long is the BioAge Labs, Inc. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
What is BioAge Labs, Inc.'s revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
